SCHEMBL2879397

SCHEMBL2879397

CS(=O)(=O)N[C@H]1CC[C@@H](c2nc3ccc(-c4ccccc4)cc3[nH]2)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 3/20 0.52
USP30 Q70CQ3 5/20 0.51
HTR2B P41595 5/20 0.49
SCD O00767 1/20 0.45
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
ROCK2 O75116 1/20 0.42
AAK1 Q2M2I8 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884212 1.00 NPY5R (0.52) NPY5RUSP30HTR2BSCDNPC1
SCHEMBL2884208 0.91 HTR2B (0.49) NPY5RUSP30HTR2BKMT2AROCK2
SCHEMBL2879392 0.91 HTR2B (0.49) NPY5RUSP30HTR2BKMT2AROCK2
SCHEMBL2879396 0.91 HTR2B (0.49) NPY5RUSP30HTR2BKMT2AROCK2
SCHEMBL2884131 0.88 NPY5R (0.49) NPY5RUSP30HTR2BNPC1RAB9A
SCHEMBL2885187 0.86 MAPT (0.49) NPY5RUSP30HTR2BSCDNPC1
SCHEMBL2884909 0.86 MAPT (0.49) NPY5RUSP30HTR2BSCDNPC1
SCHEMBL2884125 0.80 HTR2B (0.47) NPY5RUSP30HTR2BROCK2
SCHEMBL2884128 0.80 HTR2B (0.47) NPY5RUSP30HTR2BROCK2
SCHEMBL2885181 0.77 HTR2B (0.49) NPY5RHTR2BMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US claimed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US claimed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP claimed
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US disclosed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives NPY1R, NPY2R, NPY5R NPY5R 3/4885USP30 3878/4885HTR2B 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.